$CLYM
ELIEM THERAPEUTICS, INC.

2021 Q4 Form 10-Q Financial Statement

#000095017021003448 Filed on November 08, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.824M $3.394M $312.0K
YoY Change 148.8% 987.82%
% of Gross Profit
Research & Development $6.879M $5.704M $1.930M
YoY Change -49.31% 195.54%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $10.70M $9.383M $2.259M
YoY Change -29.15% 315.36%
Operating Profit -$9.383M -$2.259M
YoY Change 315.36%
Interest Expense $98.00K -$252.0K $1.000K
YoY Change -59.84% -25300.0%
% of Operating Profit
Other Income/Expense, Net $60.00K -$232.0K $1.000K
YoY Change -23300.0%
Pretax Income -$10.55M -$9.615M -$2.258M
YoY Change -29.05% 325.82%
Income Tax
% Of Pretax Income
Net Earnings -$10.55M -$9.615M -$2.258M
YoY Change -29.05% 325.82%
Net Earnings / Revenue
Basic Earnings Per Share -$0.70
Diluted Earnings Per Share -$399.7K -$616.9K -$89.04K
COMMON SHARES
Basic Shares Outstanding 26.55M 26.55M
Diluted Shares Outstanding 15.59M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $136.5M $146.0M
YoY Change
Cash & Equivalents $46.92M $62.82M $12.69M
Short-Term Investments $89.56M $83.20M
Other Short-Term Assets $11.77M $12.61M
YoY Change
Inventory
Prepaid Expenses $1.491M $1.960M
Receivables
Other Receivables
Total Short-Term Assets $148.3M $158.6M
YoY Change 573.93%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $70.00K $0.00
YoY Change -97.34%
Total Long-Term Assets $24.99M $23.62M
YoY Change 849.07%
TOTAL ASSETS
Total Short-Term Assets $148.3M $158.6M
Total Long-Term Assets $24.99M $23.62M
Total Assets $173.2M $182.3M
YoY Change 603.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.404M $2.579M
YoY Change 29.28%
Accrued Expenses $4.588M $2.979M
YoY Change 276.37%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.031M $5.590M
YoY Change 96.9%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $7.000K
YoY Change
Total Long-Term Liabilities $7.000K $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $6.031M $5.590M
Total Long-Term Liabilities $7.000K $0.00
Total Liabilities $6.038M $5.590M
YoY Change 97.13%
SHAREHOLDERS EQUITY
Retained Earnings -$75.62M -$65.10M
YoY Change 168.75%
Common Stock $242.9M $241.8M
YoY Change 7605.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $167.2M $176.7M -$12.49M
YoY Change
Total Liabilities & Shareholders Equity $173.2M $182.3M
YoY Change 603.35%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$10.55M -$9.615M -$2.258M
YoY Change -29.05% 325.82%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$7.884M -$12.97M -$6.149M
YoY Change 40.18% 110.88%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$8.051M -$106.9M $0.00
YoY Change -199.67%
Cash From Investing Activities -$8.051M -$106.9M $0.00
YoY Change -199.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 38.00K 83.14M 0.000
YoY Change -99.23%
NET CHANGE
Cash From Operating Activities -7.884M -12.97M -6.149M
Cash From Investing Activities -8.051M -106.9M 0.000
Cash From Financing Activities 38.00K 83.14M 0.000
Net Change In Cash -15.90M -36.74M -6.149M
YoY Change -315.44% 497.53%
FREE CASH FLOW
Cash From Operating Activities -$7.884M -$12.97M -$6.149M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Amendment Flag
AmendmentFlag
false
us-gaap Preferred Stock Redemption Date
PreferredStockRedemptionDate
2026-10-31
dei Entity Central Index Key
EntityCentralIndexKey
0001768446
dei Document Quarterly Report
DocumentQuarterlyReport
true
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1859713
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-83000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
0
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
245000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-59000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
2235000
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40708
dei Entity Registrant Name
EntityRegistrantName
ELIEM THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-2273741
dei Entity Address Address Line1
EntityAddressAddressLine1
23515 NE Novelty Hill Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite B221 #125
dei Entity Address City Or Town
EntityAddressCityOrTown
Redmond
dei Entity Address State Or Province
EntityAddressStateOrProvince
WA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
98053
dei City Area Code
CityAreaCode
425
dei Local Phone Number
LocalPhoneNumber
276-2300
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
ELYM
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
26554316
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
62819000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20487000
CY2021Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
83199000
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
0
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
12614000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1511000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
158632000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
21998000
CY2021Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
23619000
CY2020Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
0
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2633000
CY2021Q3 us-gaap Assets
Assets
182251000
CY2020Q4 us-gaap Assets
Assets
24631000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2579000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1086000
CY2021Q3 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
0
CY2020Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
207000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2979000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1219000
CY2021Q3 us-gaap Accounts Payable And Accrued Liabilities Fair Value Disclosure
AccountsPayableAndAccruedLiabilitiesFairValueDisclosure
32000
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Fair Value Disclosure
AccountsPayableAndAccruedLiabilitiesFairValueDisclosure
0
CY2021Q3 elym Redeemable Convertible Preferred Stock Tranche Liability
RedeemableConvertiblePreferredStockTrancheLiability
0
CY2020Q4 elym Redeemable Convertible Preferred Stock Tranche Liability
RedeemableConvertiblePreferredStockTrancheLiability
551000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
5590000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3063000
CY2021Q3 us-gaap Liabilities
Liabilities
5590000
CY2020Q4 us-gaap Liabilities
Liabilities
3063000
CY2021Q3 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000
CY2020Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
12909389
CY2021Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2021Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2020Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
7140157
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
7140157
CY2021Q3 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
0
CY2020Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
49891000
CY2021Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0
CY2020Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
46551000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26199262
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26199262
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3418751
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3418751
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
3000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
241747000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3152000
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-18000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-65071000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-28136000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
176661000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-24983000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
182251000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
24631000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5704000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1930000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15455000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4644000
CY2021Q3 elym Research And Development Expense Related Parties
ResearchAndDevelopmentExpenseRelatedParties
285000
CY2020Q3 elym Research And Development Expense Related Parties
ResearchAndDevelopmentExpenseRelatedParties
17000
elym Research And Development Expense Related Parties
ResearchAndDevelopmentExpenseRelatedParties
988000
elym Research And Development Expense Related Parties
ResearchAndDevelopmentExpenseRelatedParties
286000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3394000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
312000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8526000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
888000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
9383000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
2259000
us-gaap Operating Expenses
OperatingExpenses
24969000
us-gaap Operating Expenses
OperatingExpenses
5818000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9383000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2259000
us-gaap Operating Income Loss
OperatingIncomeLoss
-24969000
us-gaap Operating Income Loss
OperatingIncomeLoss
-5818000
CY2021Q3 elym Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liability
ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiability
0
CY2020Q3 elym Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liability
ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiability
0
elym Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liability
ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiability
11718000
elym Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liability
ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiability
0
CY2021Q3 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-252000
CY2020Q3 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
1000
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-268000
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
13000
CY2021Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
20000
CY2020Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
0
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
20000
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
0
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-232000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-11966000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
13000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-9615000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-2258000
us-gaap Net Income Loss
NetIncomeLoss
-36935000
us-gaap Net Income Loss
NetIncomeLoss
-5805000
CY2021Q3 elym Accretion Of Redeemable Convertible Preferred Stock To Redemption Value And Cumulative Preferred Stock Dividends
AccretionOfRedeemableConvertiblePreferredStockToRedemptionValueAndCumulativePreferredStockDividends
1322000
CY2020Q3 elym Accretion Of Redeemable Convertible Preferred Stock To Redemption Value And Cumulative Preferred Stock Dividends
AccretionOfRedeemableConvertiblePreferredStockToRedemptionValueAndCumulativePreferredStockDividends
461000
elym Accretion Of Redeemable Convertible Preferred Stock To Redemption Value And Cumulative Preferred Stock Dividends
AccretionOfRedeemableConvertiblePreferredStockToRedemptionValueAndCumulativePreferredStockDividends
4548000
elym Accretion Of Redeemable Convertible Preferred Stock To Redemption Value And Cumulative Preferred Stock Dividends
AccretionOfRedeemableConvertiblePreferredStockToRedemptionValueAndCumulativePreferredStockDividends
1352000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10937000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2719000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-41483000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7157000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.70
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.46
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.49
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.85
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15585611
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1863860
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7554300
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-9615000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-2258000
us-gaap Net Income Loss
NetIncomeLoss
-36935000
us-gaap Net Income Loss
NetIncomeLoss
-5805000
CY2021Q3 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-18000
CY2020Q3 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
0
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-18000
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
0
CY2021Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-9633000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-2258000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-36953000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-5805000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-24983000
CY2021Q1 elym Exercise Of Stock Options And Release Of Restricted Stock Awards
ExerciseOfStockOptionsAndReleaseOfRestrictedStockAwards
105000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
297000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-18601000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-43182000
CY2021Q2 elym Exercise Of Stock Options And Release Of Restricted Stock Awards
ExerciseOfStockOptionsAndReleaseOfRestrictedStockAwards
6000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1050000
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-8719000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-50845000
CY2021Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
83144000
CY2021Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
152759000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1236000
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-18000
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-9615000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
176661000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-5562000
CY2020Q1 elym Temporary Equity Accretion Reduction To Redemption Value
TemporaryEquityAccretionReductionToRedemptionValue
-439000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
134000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-1916000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-7783000
CY2020Q2 elym Temporary Equity Accretion Reduction To Redemption Value
TemporaryEquityAccretionReductionToRedemptionValue
-452000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
51000
CY2020Q2 us-gaap Profit Loss
ProfitLoss
-1631000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-9815000
CY2020Q3 elym Temporary Equity Accretion Reduction To Redemption Value
TemporaryEquityAccretionReductionToRedemptionValue
-461000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
49000
CY2020Q3 us-gaap Profit Loss
ProfitLoss
-2258000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-12485000
us-gaap Profit Loss
ProfitLoss
-36935000
us-gaap Profit Loss
ProfitLoss
-5805000
us-gaap Share Based Compensation
ShareBasedCompensation
2583000
us-gaap Share Based Compensation
ShareBasedCompensation
234000
elym Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liability
ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiability
11718000
elym Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liability
ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiability
0
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-11103000
elym Increase Decrease In Non Current Assets
IncreaseDecreaseInNonCurrentAssets
-2633000
elym Increase Decrease In Non Current Assets
IncreaseDecreaseInNonCurrentAssets
1361000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1494000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
82000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1760000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
611000
elym Increase Decrease In Accounts Payable And Accrued Liabilities Related Party
IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedParty
-176000
elym Increase Decrease In Accounts Payable And Accrued Liabilities Related Party
IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedParty
-59000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28188000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8474000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
106919000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-106919000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
elym Proceeds From Issuance Of Common Stock Sold In Initial Public Offering Net Issuance Costs
ProceedsFromIssuanceOfCommonStockSoldInInitialPublicOfferingNetIssuanceCosts
83144000
elym Proceeds From Issuance Of Common Stock Sold In Initial Public Offering Net Issuance Costs
ProceedsFromIssuanceOfCommonStockSoldInInitialPublicOfferingNetIssuanceCosts
0
us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
93939000
us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
111000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
177194000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
245000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-59000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
42332000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8533000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20487000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21223000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62819000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12690000
elym Conversion Of Redeemable Convertible Preferred Stock To Common Stock
ConversionOfRedeemableConvertiblePreferredStockToCommonStock
152759000
elym Conversion Of Redeemable Convertible Preferred Stock To Common Stock
ConversionOfRedeemableConvertiblePreferredStockToCommonStock
0
elym Temporary Equity Accretion Reduction To Redemption Value
TemporaryEquityAccretionReductionToRedemptionValue
0
elym Temporary Equity Accretion Reduction To Redemption Value
TemporaryEquityAccretionReductionToRedemptionValue
1352000
us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Organization</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Eliem Therapeutics, Inc. (the Company) is a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Headquartered in Redmond, Washington, the Company was incorporated on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">October 18, 2018</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> as a Delaware corporation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2018-10-18
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-2
CY2021Q3 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
152800000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-65100000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of the interim condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Key management estimates include those related to the valuation of assets acquired, accrual of research and development expenses, the valuation of stock-based awards, the valuation of common stock and redeemable convertible preferred stock, and the valuation of redeemable convertible preferred stock tranche liabilities. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</span></p>
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1511000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of Credit Risk</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company’s cash is held by two financial institutions in the United States (U.S.) and two financial institutions in the United Kingdom (U.K.). The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company’s deposits held in the U.S. and U.K. may exceed the Federal Depository Insurance Corporation and Financial Services Compensation Scheme, respectively, insured limits. The Company has investments in money market funds, U.S. government debt securities, commercial paper, and corporate bonds with high-quality accredited financial institutions.</span>
CY2021Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
145230000
CY2020Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
551000
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2021Q3 us-gaap Other Assets
OtherAssets
1050000
CY2020Q4 us-gaap Other Assets
OtherAssets
11000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
12614000
CY2021Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0
CY2021Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0
CY2021Q3 elym Recoverable Research And Development Tax Credits
RecoverableResearchAndDevelopmentTaxCredits
6943000
CY2020Q4 elym Recoverable Research And Development Tax Credits
RecoverableResearchAndDevelopmentTaxCredits
0
CY2021Q3 elym Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
2661000
CY2020Q4 elym Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
1500000
CY2021Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1960000
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
0
CY2021Q3 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
1443000
CY2020Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
592000
CY2021Q3 elym Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
1278000
CY2020Q4 elym Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
627000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
290000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
0
CY2021Q3 elym Accrued Liabilities Current Including Related Party Transactions
AccruedLiabilitiesCurrentIncludingRelatedPartyTransactions
3011000
CY2020Q4 elym Accrued Liabilities Current Including Related Party Transactions
AccruedLiabilitiesCurrentIncludingRelatedPartyTransactions
1219000
CY2020Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
12909389
CY2020Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
7140157
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
7140157
CY2020Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
46551000
CY2020Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
49891000
elym Cumulative Dividends Receive
CumulativeDividendsReceive
0.08
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
0
CY2020Q4 elym Redeemable Convertible Preferred Stock Tranche Liability
RedeemableConvertiblePreferredStockTrancheLiability
551000
elym Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liability
ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiability
11718000
elym Reclassification Of Redeemable Convertible Preferred Stock Tranche Liability Upon Settlement
ReclassificationOfRedeemableConvertiblePreferredStockTrancheLiabilityUponSettlement
-12269000
CY2021Q3 elym Redeemable Convertible Preferred Stock Tranche Liability
RedeemableConvertiblePreferredStockTrancheLiability
0
CY2021Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
CY2020Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
13000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
100000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
38000
CY2021Q3 us-gaap Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals
OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals
600000
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2023-06-30
elym Executive Officer Earning Contribution
ExecutiveOfficerEarningContribution
0.15
CY2021Q3 elym Fair Market Value Common Stock Percentage
FairMarketValueCommonStockPercentage
0.85
CY2021Q3 elym Fair Market Value Common Stock Percentage
FairMarketValueCommonStockPercentage
0.85
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
435342
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.52
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y2M8D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
415000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2386990
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.11
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
25551
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.86
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
59466
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.86
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
150000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2737315
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.74
elym Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term3
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3
P9Y3M29D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
41727000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2737315
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
2.74
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P9Y3M29D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
41727000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
206339
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.31
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y4M20D
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3646000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0094
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0113
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
21750
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1236000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
49000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2583000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
234000
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
13300
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y2M8D
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-9615000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-2258000
us-gaap Net Income Loss
NetIncomeLoss
-36935000
us-gaap Net Income Loss
NetIncomeLoss
-5805000
CY2021Q3 elym Accretion Of Redeemable Convertible Preferred Stock To Redemption Value And Cumulative Preferred Stock Dividends
AccretionOfRedeemableConvertiblePreferredStockToRedemptionValueAndCumulativePreferredStockDividends
1322000
CY2020Q3 elym Accretion Of Redeemable Convertible Preferred Stock To Redemption Value And Cumulative Preferred Stock Dividends
AccretionOfRedeemableConvertiblePreferredStockToRedemptionValueAndCumulativePreferredStockDividends
461000
elym Accretion Of Redeemable Convertible Preferred Stock To Redemption Value And Cumulative Preferred Stock Dividends
AccretionOfRedeemableConvertiblePreferredStockToRedemptionValueAndCumulativePreferredStockDividends
4548000
elym Accretion Of Redeemable Convertible Preferred Stock To Redemption Value And Cumulative Preferred Stock Dividends
AccretionOfRedeemableConvertiblePreferredStockToRedemptionValueAndCumulativePreferredStockDividends
1352000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10937000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2719000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-41483000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7157000
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15585611
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1863860
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7554300
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1859713
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.70
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.46
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.49
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.85
us-gaap Preferred Stock Conversion Basis
PreferredStockConversionBasis
1-for-1
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3085954
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3085954
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4483190
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4483190
CY2021Q3 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
300000
CY2020Q3 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
17000
us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
1000000.0
us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
300000

Files In Submission

Name View Source Status
0000950170-21-003448-index-headers.html Edgar Link pending
0000950170-21-003448-index.html Edgar Link pending
0000950170-21-003448.txt Edgar Link pending
0000950170-21-003448-xbrl.zip Edgar Link pending
elym-20210930.htm Edgar Link pending
elym-20210930.xsd Edgar Link pending
elym-20210930_cal.xml Edgar Link unprocessable
elym-20210930_def.xml Edgar Link unprocessable
elym-20210930_htm.xml Edgar Link completed
elym-20210930_lab.xml Edgar Link unprocessable
elym-20210930_pre.xml Edgar Link unprocessable
elym-ex31_1.htm Edgar Link pending
elym-ex31_2.htm Edgar Link pending
elym-ex32_1.htm Edgar Link pending
elym-ex32_2.htm Edgar Link pending
elym-ex3_2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img155835445_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending